35
Participants
Start Date
August 31, 2007
Primary Completion Date
January 31, 2010
Study Completion Date
August 31, 2012
everolimus
Patients receive oral everolimus once daily on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
molecular response by PCR
Bone marrow and peripheral blood samples are collected periodically and analyzed for molecular response by PCR. Molecular studies are also performed on DNA level formalin-fixed paraffin-embedded tissue
Istituto Oncologico della Svizzera Italiana, Bellinzona
Onkozentrum - Klinik im Park, Zurich
European Institute of Oncology, Milan
Hopital Haut Leveque, Pessac
Centre Hospitalier Universitaire Bretonneau de Tours, Tours
CHU de Grenoble - Hopital de la Tronche, Grenoble
University of Bologna Medical School, Bologna
Institut Gustave Roussy, Villejuif
Hirslanden Klinik Aarau, Aarau
Kantonsspital Baden, Baden
Universitaetsspital-Basel, Basel
Inselspital Bern, Bern
Kantonsspital Graubuenden, Chur
Centre Hospitalier Universitaire Vaudois, Lausanne
Kantonsspital Olten, Olten
Kantonsspital - St. Gallen, Sankt Gallen
Hopitaux Universitaires de Geneve, Thonex-Geneve
Kantonsspital Winterthur, Winterthur
Klinik Hirslanden, Zurich
City Hospital Triemli, Zurich
UniversitaetsSpital Zuerich, Zurich
Swiss Cancer Institute
OTHER